Amended Claims

1. The compound of general formula (I)



wherein

ring A is a cycloalkyl or heterocyclyl group; and

in B-Y, Y is -O-, -C(O)-, -CH_2-, -NH-, -C_{1-4}alkyl-N(R^{18})- or bond ~~if ring B is present~~ and ring B is an optionally substituted heteroaryl, aryl or heterocyclyl group; or

B-Y- jointly represents -N(C_{1-4}alkyl)$_2$, C(O)OC_{1-4}alkyl, C_{1-4}alkyl optionally substituted with halogen, C_{1-4}alkoxy group or halogen ~~if ring B is not present~~;

~~ring B is an optionally substituted heteroaryl, aryl or heterocyclyl group;~~

or B-Y-A- jointly represents a 3*H*-spiro[2-benzofuran-1,4'-piperidin-1'-yl]; or



group; or


group; or


group;

R^1 is a hydrogen, halogen, C_{1-4}alkyl, C_{1-4}alkoxy, CF_3 or CN;

R^2 is a hydrogen or C_{1-4}alkyl group;

R^3 is a NR^4R^5, OR^6 group or halogen;

or R^2 and R^3 jointly represent -O-$(CH_2)_m$-O-, oxo or =N-OH group;

R^4 and R^5 is independently a hydrogen; C_{1-4}alkyl optionally substituted with OH, halogen, cycloalkyl, optionally substituted aryl or NR^8R^9 group; Cy^1; C(O)R^7; -S(O_2)R^{10} or C_{2-4}alkynyl group;

or R^4 and R^5 taken together with the N to which they are attached form a heterocycle;

R^6 is a hydrogen; C_{1-4}alkyl optionally substituted with OH, halogen, Cy^2, C_{1-4}alkoxy, -S(O_2)-C_{1-4}alkyl or $NR^{11}R^{12}$ group; C(O)R^{13}; Si(CH_3)$_2$-*t*-butyl or C_{2-4}alkynyl group;

R^7 is a C_{1-4}alkyl optionally substituted with OH, CN, halogen, Cy^3 or $NR^{11}R^{12}$ group; C_{1-4}alkoxy, C_{2-4}alkenyl, Cy^3 or $N(C_{1-4}alkyl)_2$ group;

R^8 and R^9 is independently a hydrogen, C_{1-4}alkyl or $C(O)OR^{21}$ group;

R^{10} is a C_{1-4}alkyl, OH or $NR^{14}R^{15}$ group;

R^{11} and R^{12} is independently a hydrogen or C_{1-4}alkyl group;

or R^{11} and R^{12} taken together with the N to which they are attached form an optionally substituted heterocycle;

R^{13} is a C_{1-4}alkyl optionally substituted with CN or $NR^{19}R^{20}$ group; Cy^3 or $NR^{16}R^{17}$ group;

R^{14} and R^{15} is independently a hydrogen or C_{1-4}alkyl group;

R^{16} and R^{17} is independently a hydrogen, C_{1-4}alkyl, or optionally substituted aryl group;

or R^{16} and R^{17} taken together with the N to which they are attached form a heterocycle;

R^{18} and R^{21} is a hydrogen or C_{1-4}alkyl group;

R^{19} and R^{20} is independently a hydrogen or C_{1-4}alkyl group;

Cy^1 is an optionally substituted cycloalkyl, heterocyclyl or heteroaryl group;

Cy^2 is an optionally substituted aryl or cycloalkyl group;

Cy^3 is an optinally substituted aryl, cycloalkyl, heterocyclyl or heteroaryl group;

X is a C_{1-4}alkyl, aryl or heteroaryl group;

Z is a C_{1-4}alkyl group;

m is 2, 3, 4 or 5

and/or salts thereof and/or geometric isomers thereof and/or stereoisomers thereof and/or enantiomers thereof and/or racemates thereof and/or diastereomers thereof and/or ~~biologically active metabolites thereof and/or prodrugs thereof and/or~~ solvates thereof and/or hydrates thereof and/or polymorphs thereof.

2. The compound according to claim 1, wherein R^1 is a hydrogen, fluorine, chlorine, bromine, methyl, methoxy, CF_3 or CN.

3. The compound according to any of claims 1 to 2, wherein

ring A is a 3- to 6-membered saturated carbocyclic group or a 4- to 7-membered saturated heterocycle containing 1 or 2 N;

ring B is an optionally substituted 6- or 5-membered mono-heteroaryl group, 6- to 10-membered aromatic carbocycle, or 4- to 7-membered saturated, monocyclic, bicyclic, fused and/or bridged heterocycle containing 1, 2 or 3 heteroatoms selected from O, S or N;

or B-Y-A- jointly represents a 3*H*-spiro[2-benzofuran-1,4'-piperidin-1'-yl]; or

 group; or  group; or  group; X is isopropyl group; Z is methyl group.

~~4. The compound according to any of claims 1 to 3, wherein ring B is an optionally substituted 6-membered mono-heteroaryl group, or 5- to 6-membered saturated, monocyclic heterocycle containing 1 or 2 heteroatoms selected from O, S or N.~~

~~5. The compound according to any of claims 1 to 4, wherein Y is -O-, -C(O)-, -CH_2-, -NH-, -C_{1-4}alkyl-N(R^{18})- or a single bond if ring B is present and R^{18} is hydrogen or methyl group.~~

~~6~~4. The compound according to any of claims 1 to ~~5~~3, wherein ring A is a 4- to 6-membered saturated carbocyclic group or a 4- to 7-membered saturated heterocycle containing 1 or 2 N attached via a ring nitrogen to Y or to the triazole ring of the 5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-a][1]benzazepine core.

~~7~~5. The compound according to any of claims 1 to ~~6~~4, wherein ring A is cyclohexyl, Y is -O-, ring B is pyridin-2-yl and R^1 is chlorine.

~~8. The compound according to any of claims 1 to 6, wherein ring A is piperidine, piperazine, or pyrrolidine, Y is -O-, -C(O)-, -CH_2-, or a single bond, ring B is pyridine, piperidine, tetrahydrofuran, or tetrahydropyran, and R^1 is chlorine.~~

~~9. The compound according to any of claims 1 to 3, wherein Y is -N(C_{1-4}alkyl)$_2$, C(O)OC_{1-4}alkyl, C_{1-4}alkyl optionally substituted with halogen, C_{1-4}alkoxy group or halogen and ring B is not present.~~

~~10. The compound according to claim 9, wherein ring A is a 4- to 6-membered saturated carbocyclic group.~~

~~11. The compound according to claim 10, wherein Y is one group selected from the group consisting of -N(C_{1-4}alkyl)$_2$, C(O)OC_{1-4}alkyl, C_{1-4}alkyl optionally substituted with halogen,~~
~~C_{1-4}alkoxy group and halogen.~~

~~12. The compound according to claim 10, wherein Y is two groups selected from the group consisting of C_{1-4}alkyl optionally substituted with halogen, C_{1-4}alkoxy group and halogen.~~

~~136~~. The compound according to any of claims 1 to ~~125~~, wherein

R^2 is a hydrogen or C_{1-4}alkyl group;

R^3 is a NR^4R^5 group;

R^4 and R^5 is independently a hydrogen; C_{1-4}alkyl optionally substituted with OH, halogen, cycloalkyl, optionally substituted aryl or NR^8R^9 group; Cy^1; $C(O)R^7$; $-S(O_2)R^{10}$ or C_{2-4}alkynyl group;

or R^4 and R^5 taken together with the N to which they are attached form a heterocycle;

R^7 is a C_{1-4}alkyl optionally substituted with OH, CN, halogen, Cy^3 or $NR^{11}R^{12}$ group; C_{1-4}alkoxy, C_{2-4}alkenyl, Cy^3 or $N(C_{1-4}alkyl)_2$ group;

R^8 and R^9 is independently hydrogen, C_{1-4}alkyl or $C(O)OR^{21}$ group;

R^{10} is a C_{1-4}alkyl, OH or $NR^{14}R^{15}$ group;

R^{11} and R^{12} is independently a hydrogen or C_{1-4}alkyl group;

or R^{11} and R^{12} taken together with the N to which they are attached form an optionally substituted heterocycle;

R^{14} and R^{15} is independently a hydrogen or C_{1-4}alkyl group;

R^{21} is a hydrogen or C_{1-4}alkyl group;

Cy^1 is an optionally substituted cycloalkyl, heterocyclyl or heteroaryl group;

Cy^3 is an optionally substituted aryl, cycloalkyl, heterocyclyl or heteroaryl group.

~~147~~. The compound according to claim ~~136~~, wherein R^2 is a hydrogen and ~~.~~

~~15. The compound according to claim 14, wherein~~

~~R^4 and R^5 is independently a hydrogen; $C(O)R^7$; C_{1-4}alkyl optionally substituted with OH, halogen, cycloalkyl, optionally substituted aryl or NR^8R^9 group; R^8 and R^9 is independently hydrogen or C_{1-4}alkyl group.~~

~~16. The compound according to claim 15, wherein~~ R^4 and R^5 ~~are~~ is independently a hydrogen ors ~~.~~

~~17. The compound according to claim 15, wherein R^4 is a hydrogen, R^5 is~~ a C_{1-4}alkyl group.

~~18. The compound according to claim 15, wherein R^4 and R^5 are C_{1-4}alkyl groups.~~

~~19. The compound according to claim 15, wherein~~
~~R^4 is a hydrogen;~~
~~R^5 is a $C(O)R^7$ group;~~
~~R^7 is a C_{1-4}alkyl optionally substituted with OH, CN, halogen, Cy^3 or $NR^{11}R^{12}$ group; C_{1-4}alkoxy, C_{2-4}alkenyl, Cy^3 or $N(C_{1-4}alkyl)_2$ group;~~
~~R^{11} and R^{12} is independently a hydrogen or C_{1-4}alkyl group;~~
~~or R^{11} and R^{12} taken together with the N to which they are attached form an optionally substituted heterocycle;~~
~~Cy^3 is an optionally substituted aryl, cycloalkyl, heterocyclyl or heteroaryl group.~~

~~20. The compound according to claim 14, wherein R^4 is a hydrogen, R^5 is a Cy^1 and Cy^1 is an optionally substituted cycloalkyl, heterocyclyl or heteroaryl group.~~

~~21. The compound according to claim 14, wherein~~
~~R^4 is a hydrogen or C_{1-4}alkyl group;~~
~~R^5 is a $S(O_2)R^{10}$ group;~~
~~R^{10} is a C_{1-4}alkyl, OH or $NR^{14}R^{15}$ group;~~
~~R^{14} and R^{15} is independently a hydrogen or C_{1-4}alkyl group.~~

~~22. The compound according to claim 14, wherein R^4 and R^5 taken together with the N to which they are attached form a 4- to 7-membered heterocycle containing optionally 1, 2 or 3 heteroatoms selected from O, S or N.~~

~~23~~8. The compound according to any of claims 1 to ~~12~~5, wherein
R^2 is a hydrogen or C_{1-4}alkyl group;
R^3 is an OR^6 group;
R^6 is a hydrogen; C_{1-4}alkyl group optionally substituted with OH, halogen, Cy^2, C_{1-4}alkoxy, -$S(O)_2$-C_{1-4}alkyl or $NR^{11}R^{12}$ group; $C(O)R^{13}$, $Si(CH_3)_2$-*t*-butyl or C_{2-4}alkynyl group;
R^{11} and R^{12} is independently a hydrogen or C_{1-4}alkyl group;
or R^{11} and R^{12} taken together with the N to which they are attached form an optionally substituted heterocycle;
R^{13} is a C_{1-4}alkyl group optionally substituted with CN or $NR^{19}R^{20}$ group; Cy^3 or $NR^{16}R^{17}$ group;
R^{16} and R^{17} is independently a hydrogen, C_{1-4}alkyl or optionally substituted aryl group;
or R^{16} and R^{17} taken together with the N to which they are attached form a heterocycle;
R^{19} and R^{20} is independently a hydrogen or C_{1-4}alkyl group;
Cy^2 is an optionally substituted aryl or cycloalkyl group.

249. The compound according to claim 238, wherein R^2 is a hydrogen and -.

25. The compound according to claim 24, wherein R^6 is a hydrogen or -.

26. The compound according to claim 24, wherein R^6 is a C_{1-4}alkyl group.

27. The compound according to claim 24, wherein
R^6 is a $C(O)R^{13}$ group;
R^{13} is a C_{1-4}alkyl group optionally substituted with CN or $NR^{19}R^{20}$ group; Cy^3 or $NR^{16}R^{17}$ group;
R^{16} and R^{17} is independently a hydrogen, C_{1-4}alkyl or optionally substituted aryl group;
or R^{16} and R^{17} taken together with the N to which they are attached form a heterocycle;
R^{19} and R^{20} is independently a hydrogen or C_{1-4}alkyl group.

2810. The compound according to any of claims 13 6 to 279, wherein the absolute configuration of the carbon at position 5 in the 5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-a][1]benzazepine core is (*S*) or (*R*).

29. The compound according to any of claims 13 to 27, wherein the absolute configuration of the carbon at position 5 in the 5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-a][1]benzazepine core is (*S*).

3011. The compound according to any of claims 1 to 125, wherein R^2 and R^3 jointly represent -O-$(CH_2)_m$-O-, oxo or =N-OH group, m is 2, 3, 4 or 5.

3112. The compound according to claim 3011, wherein R^2 and R^3 jointly represent -O-$(CH_2)_m$-O- and m is 2.

3213. The compound according to any of claims 1 to 3112, wherein the compound is selected from the group consisting of:

tert-butyl [8-chloro-1-[1-(pyridin-2-yl)piperidin-4-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl] carbamate,

8-chloro-1-[1-(pyridin-2-yl)piperidin-4-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

N-[8-chloro-[1-(pyridin-2-yl)piperidin-4-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl]acetamide,

N-(8-chloro-[1-(pyridin-2-yl)piperidin-4-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl)-2-methylpropanamide,

tert-butyl {8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*]benzazepine-5-yl}carbamate,

8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

N-{8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}acetamide,

N-{8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}glycinamide,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}glycinamide,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}glycinamide,

(2*S*)-2-amino-*N*-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2-phenylacetamide,

(2*R*)-2-amino-*N*-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2-phenylacetamide,

N-{8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2-hydroxyacetamide,

3-{8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-1,1-dimethylurea,

N-{8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-N^2,N^2-dimethylglycinamide,

N-{8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}methanesulfonamide,

N-{8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-*N*-methylmethanensulfonamide,

N'-{8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-*N*,*N*-dimethylsulfamide,

8-chloro-*N*-methyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-chloro-*N*,*N*-dimethyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-chloro-*N*-ethyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-chloro-*N*-(propan-2-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

(5*S*)-8-chloro-*N*-(propan-2-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

(5*R*)-8-chloro-*N*-(propan-2-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-chloro-*N*-cyclobutyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-chloro-*N*-(oxetan-3-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-*N*-(tetrahydro-2*H*-pyran-4-yl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-chloro-*N*-(4,4-difluorcyclohexyl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-methoxy-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine hydrochloride,

8-methoxy-*N*-(propan-2-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

tert-butyl {1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-8-(trifluoromethyl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}carbamate,

1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-8-(trifluoromethyl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine hydrochloride,

N,*N*-dimethyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-8-(trifluoromethyl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

N-(propan-2-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-8-(trifluoromethyl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-methyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-methyl-*N*-(propan-2-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-a][1]benzazepine-5-amine,

8-bromo-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-a][1]benzazepine-5-amine,

8-bromo-*N*-(propan-2-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-a][1]benzazepine-5-amine,

8-chloro-1-(3,3-difluorocyclobutyl)-*N*-(propan-2-yl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-chloro-1-(4,4-difluorocyclohexyl)-*N*-(propan-2-yl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-chloro-1-[*trans*-4-(trifluoromethyl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-chloro-*N*-(propan-2-yl)-1-[*trans*-4-(trifluoromethyl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8-bromo-1-[*trans*-4-(trifluoromethyl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-a][1]benzazepine-5-amine,

8-bromo-*N*-(propan-2-yl)-1-[*trans*-4-(trifuoromethyl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-a][1]benzazepine-5-amine,

1'-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-8'-(trifluoromethyl)-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-8-(trifluoromethyl)-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5(6*H*)-one,

1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-8-(trifluoromethyl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-ol,

5-methoxy-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-8-(trifluoromethyl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

5-(cyclopropylmethoxy)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-8-(trifluoromethyl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

5-{[*tert*-butyl(dimethyl)silyl]oxy}-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8'-chloro-1'-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5(6*H*)-one,

8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-ol,

(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-ol,

(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-ol,

8-chloro-5-methoxy-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

5-(cyclopropylmethoxy)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

2-({8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}oxy)-*N*,*N*-dimethylethanamine,

8'-chloro-1'-[*trans*-4-(trifluoromethyl)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8'-bromo-1'-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-a][1]benzazepine],

1'-[t*rans*-4-(pyridin-2-yloxy)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8-bromo-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5(6*H*)-one,

8-bromo-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-ol,

1'-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-a][1]benzazepin]-8'-carbonitrile,

(5*S*)-8-chloro-*N*,*N*-dimethyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

(5*S*)-*N*-{8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}acetamide,

8'-chloro-1'-[*trans*-4-(pyridin-2-ylmethyl)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

[*trans*-4-(8'-chloro-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine]-1'-yl)cyclohexyl](pyrrolidin-1-yl)methanone,

8-chloro-1-[*trans*-4-(trifluoromethyl)cyclohexyl]-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5(6*H*)-one,

8-chloro-1-[*trans*-4-(trifluoromethyl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-ol,

(cis)-8-(8'-chloro-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepin]-1'-yl)-3-methyl-1-oxa-3-azaspiro[4.5]decan-2-one,

8-chloro-5-methoxy-1-[*trans*-4-(trifluoromethyl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

(*trans*)-8-(8'-chloro-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepin]-1'-yl)-3-methyl-1-oxa-3-azaspiro[4.5]decan-2-one,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-*N*-methylmethanesulfonamide,

(5*S*)-8-chloro-*N*-ethyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

(5*S*)-8-chloro-*N*-methyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

8'-chloro-1'-[1-(pyrimidin-2-yl)azetidin-3-yl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-4-fluorobenzamide,

8'-bromo-1'-[*trans*-4-(trifluoromethyl)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

5-(propan-2-ylamino)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-8-carbonitrile trifluoroacetate,

(5*S*)-8-chloro-*N*-(4-fluorobenzyl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine-5-amine,

1'-[*trans*-4-(trifluoromethyl)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine]-8'-carbonitrile,

[*trans*-4-(8'-bromo-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-a][1]benzazepin]-1'-yl)cyclohexyl](piperidin-1-yl)methanone,

methyl *trans*-4-(8-bromo-5-oxo-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-1-yl)cyclohexane carboxilate,

8-bromo-1-[*trans*-4-(piperidin-1-ylcarbonyl)cyclohexyl]-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5(6*H*)-one,

8'-chloro-1'-[*trans*-4-(trifluoromethyl)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

1'-[*trans*-4-(piperidin-1-ylcarbonyl)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepin]-8'-carbonitrile,

8'-chloro-1'-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8-bromo-1-[*trans*-4-(trifluoromethyl)cyclohexyl]-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5(6*H*)-one,

[*trans*-4-(8-bromo-5-hydroxy-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-1-yl)cyclohexyl](piperidin-1-yl)methanone,

8-bromo-1-[*trans*-4-(trifluoromethyl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-ol,

1'-(1,4'-bipiperidin-1'-yl)-8'-chloro-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

tert-butyl [1-(1,4'-bipiperidin-1'-yl)-8-chloro-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl]carbamate,

8'-fluoro-1'-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

(5*S*)-8-chloro-*N*-(4-fluorobenzyl)-*N*-methyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}prop-2-enamide,

(5*R*)-8-chloro-*N*-ethyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

(5*R*)-8-chloro-*N*-methyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

(5*R*)-8-chloro-*N*,*N*-dimethyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5(6*H*)-one,

(5*S*)-8-chloro-5-methoxy-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

(5*R*)-8-chloro-5-methoxy-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-5-(propan-2-yloxy)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8'-chloro-1'-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxepane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-ol,

[*trans*-4-(8'-chloro-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepin]-1'-yl)cyclohexyl](morpholin-4-yl)methanone

5-methoxy-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-fluoro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5(6*H*)-one,

8-fluoro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-ol,

tert-butyl {8-chloro-1-[*trans*-4-(morpholin-4-yl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}carbamate,

8-chloro-1-[*trans*-4-(morpholin-4-yl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8-chloro-1-[*trans*-4-(morpholin-4-yl)cyclohexyl]-*N*-(propan-2-yl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

(5*r*,8*r*)-8-(8'-chloro-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepin]-1'-yl)-2-(propan-2-yl)-2-azaspiro[4.5]decan-1-one,

(5*r*,8*r*)-8-(8-chloro-5-hydroxy-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-1-yl)-2-(propan-2-yl)-2-azaspiro[4.5]decan-1-one,

(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5-(pyrrolidin-1-yl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2,2-dimethylpropanamide,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}cyclopropanecarboxamide,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2-methylpropanamide,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}cyclobutanecarboxamide,

(5*S*)-8-chloro-5-(morpholin-4-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2,2-dimethylpropanamide,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2-methylpropanamide,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}cyclobutanecarboxamide,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}cyclopropanecarboxamide,

(5*S*)-8-chloro-5-(piperidin-1-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

(5*S*)-*N*-(butan-2-yl)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

(5*s*,8*s*)-8-(8'-chloro-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepin]-1'-yl)-2-(propan-2-yl)-2-azaspiro[4.5]decan-1-one,

8-chloro-5-methoxy-1-[*trans*-4-(morpholin-4-yl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-5-ethoxy-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

(5*R*)-8-chloro-5-methoxy-1-[*trans*-4-(trifluoromethyl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

(5*S*)-8-chloro-5-methoxy-1-[*trans*-4-(trifluoromethyl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-fluoro-5-methoxy-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-*N*-(propan-2-yl)-1-[1-(pyridin-2-yl)piperidin-4-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

2-({8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}oxy)ethanol,

(5*S*)-8-chloro-*N*,*N*-diethyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8-chloro-*N*-methyl-*N*-(propan-2-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

tert-butyl {8-chloro-1-[4-(3-chloropyridin-2-yl)piperazin-1-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}carbamate,

tert-butyl 4-(8-chloro-5-methoxy-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-1-yl)piperidine-1-carboxylate,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-D-valinamide,

tert-butyl {1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}carbamate,

tert-butyl {8-fluoro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}carbamate,

1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8-fluoro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8-fluoro-*N*-(propan-2-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8-fluoro-*N*,*N*-dimethyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

N,*N*-dimethyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8'-fluoro-1'-[*trans*-4-(trifluoromethyl)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

N-(propan-2-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}tetrahydro-2*H*-pyran-4-carboxamide,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2-methylbutanamide,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-N^3,N^3-dimethyl-β-alaninamide,

(5*S*)-8-chloro-*N*-cyclopentyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8'-chloro-1'-(1'*H*,3*H*-spiro[2-benzofuran-1,4'-piperidin]-1'-yl)-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8-chloro-1-(1'*H*,3*H*-spiro[2-benzofuran-1,4'-piperidin]-1'-yl)-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5(6*H*)-one,

8'-chloro-1'-[4-(pyridin-2-yloxy)piperidin-1-yl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2,2-dimethylbutanamide,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2-hydroxy-2-methylpropanamide,

(5*S*)-8-chloro-*N*-ethyl-*N*-methyl-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

(5*S*)-8-chloro-*N*-(2-methylpropyl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8'-chloro-1'-[*trans*-4-(morpholin-4-yl)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine] hydrochloride,

8-chloro-*N*,*N*-dimethyl-1-(1'*H*,3*H*-spiro[2-benzofuran-1,4'-piperidin]-1'-yl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8'-chloro-1'-[4-(3-chloropyridin-2-yl)piperazin-1-yl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

(5*S*)-8-chloro-*N*-(2,2-dimethylpropyl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

[*trans*-4-(8-chloro-5-methoxy-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-1-yl)cyclohexyl](4-methylpiperazin-1-yl)methanone,

(5*R*)-8-chloro-5-(morpholin-4-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}acetamide,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2-hydroxy-2-methylpropanamide,

8-chloro-5-methoxy-1-[1-(tetrahydro-2*H*-pyran-4-yl)piperidin-4-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8'-chloro-1'-[4-(pyridin-2-yl)piperazin-1-yl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8-chloro-1-(1'*H*,3*H*-spiro[2-benzofuran-1,4'-piperidin]-1'-yl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-ol,

8-chloro-1-[4-(3-chloropyridin-2-yl)piperidin-1-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-ol,

(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5-(pyrrolidin-1-yl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-5-methoxy-1-{1-[(3*S*)-tetrahydrofuran-3-yl]piperidin-4-yl}-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

(5*R*)-8-fluoro-5-methoxy-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

(5*S*)-8-fluoro-5-methoxy-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-5-methoxy-1-{1-[(3*R*)-tetrahydrofuran-3-yl]piperidin-4-yl}-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-N^3,N^3-dimethyl-β-alaninamide,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}tetrahydro-2*H*-pyran-4-carboxamide,

8-chloro-1-[4-(pyridin-2-yloxy)piperidin-1-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-ol,

8-chloro-5-methoxy-1-[*trans*-4-(4-methylpiperazin-1-yl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-5-methoxy-1-[*cis*-4-(4-methylpiperazin-1-yl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-5-methoxy-1-[1-(pyridin-3-ylmethyl)pyrrolidin-3-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-5-methoxy-1-[1-(pyridin-2-ylmethyl)pyrrolidin-3-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2-cyanoacetamide,

[3-(8-chloro-5-methoxy-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-1-yl)pyrrolidin-1-yl](pyridin-3-yl)methanone,

8'-chloro-1'-{1-[(3*R*)-tetrahydrofuran-3-yl]piperidin-4-yl}-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

[3-(8-chloro-5-methoxy-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-1-yl)pyrrolidin-1-yl](pyridin-2-yl)methanone,

trans-4-(8'-chloro-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepin]-1'-yl)-*N*,*N*-dimethylcyclohexanamine,

8-chloro-5-methoxy-1-(1'*H*,3*H*-spiro[2-benzofuran-1,4'-piperidin]-1'-yl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-1-[4-(3-chloropyridin-2-yl)piperazin-1-yl]-5-methoxy-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

N-[*trans*-4-(8'-chloro-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepin]-1'-yl)cyclohexyl]pyridin-2-amine,

N'-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-*N*,*N*-dimethylethane-1,2-diamine,

8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl acetate,

2-({(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}amino)ethanol,

8-chloro-5-methoxy-1-[4-(pyridin-2-yloxy)piperidin-1-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8'-chloro-1'-(*trans*-4-methoxy-4-methylcyclohexyl)-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

(5*S*)-8-chloro-*N*-(cyclopropylmethyl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-1-methylpiperidine-4-carboxamide,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2,2,2-trifluoroacetamide,

8-chloro-5-(2-methoxyethoxy)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-1-(4-methoxy-4-methylcyclohexyl)-*N*-(propan-2-yl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8'-chloro-1'-(*trans*-4-methoxy-4-methylcyclohexyl)-4'*H*,6'*H*-spiro[1,3-dioxane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8'-chloro-1'-(*cis*-4-methoxy-4-methylcyclohexyl)-4'*H*,6'*H*-spiro[1,3-dioxane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8-chloro-5-fluoro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-5-[2-(methylsulfonyl)ethoxy]-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-*N*-hydroxy-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5(6*H*)-imine,

(5*S*)-8-chloro-*N*-methyl-*N*-(prop-2-yn-1-yl)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-3,3-difluorocyclobutanecarboxamide,

8-chloro-5-(prop-2-yn-1-yloxy)-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl 4,4-difluorocyclohexanecarboxylate,

8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl 3,3-difluorocyclobutanecarboxylate,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-4,4-difluorocyclohexanecarboxamide,

8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl cyanoacetate,

8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl *N*,*N*-dimethylglycinate,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-2,2,2-trifluoroacetamide,

1-[*cis*-4-(8-chloro-5-methoxy-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-1-yl)cyclohexyl]pyrrolidin-2-one,

1-[*trans*-4-(8-chloro-5-methoxy-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-1-yl)cyclohexyl]pyrrolidin-2-one,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-3,3-difluorocyclobutanecarboxamide,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-4,4-difluorocyclohexanecarboxamide,

8-chloro-5-methoxy-1-[*cis*-4-methoxy-4-(trifluoromethyl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-5-methoxy-1-[*trans*-4-methoxy-4-(trifluoromethyl)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-*N*-(2,2,2-trifluoroethyl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

N-{(5*S*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-3-methyloxetane-3-carboxamide,

N-{(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}-3-methyloxetane-3-carboxamide,

trans-4-(8'-chloro-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepin]-1'-yl)-*N*-(4-methoxybenzyl)cyclohexanamine,

tert-butyl [2-({(5*R*)-8-chloro-1-[*trans*-4-(pyridin-2-yloxy)cyclohexyl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-yl}amino)ethyl]carbamate,

8'-chloro-1'-(*trans*-4-ethoxy-4-ethylcyclohexyl)-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

trans-4-(8'-chloro-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepin]-1'-yl)-*N*-(4-methoxybenzyl)-*N*-methylcyclohexanamine,

8'-chloro-1'-[1-(pyridin-3-ylmethyl)pyrrolidin-3-yl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8-chloro-5-methoxy-1-[4-(pyridin-2-yl)piperazin-1-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-1-(*trans*-4-ethyl-4-methoxycyclohexyl)-*N*,*N*-dimethyl-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8-chloro-1-(*trans*-4-ethoxy-4-methylcyclohexyl)-*N*,*N*-dimethyl-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8'-chloro-1'-[*trans*-4-methoxy-4-(trifluoromethyl)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8'-chloro-1'-[*cis*-4-methoxy-4-(trifluoromethyl)cyclohexyl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8'-chloro-1'-(*trans*-4-ethoxy-4-methylcyclohexyl)-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8'-chloro-1'-(*trans*-4-ethoxy-4-propylcyclohexyl)-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8'-chloro-1'-[1-(pyridin-2-ylmethyl)pyrrolidin-3-yl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8'-chloro-1'-(*cis*-4-ethyl-4-methoxycyclohexyl)-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8'-chloro-1'-(*trans*-4-ethyl-4-methoxycyclohexyl)-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8'-chloro-1'-(*trans*-4-methoxy-4-propylcyclohexyl)-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8'-chloro-1'-(*cis*-4-methoxy-4-propylcyclohexyl)-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8-chloro-1-(*trans*-4-ethoxy-4-ethylcyclohexyl)-*N*-(propan-2-yl)-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8-chloro-1-(*trans*-4-ethoxy-4-ethylcyclohexyl)-*N*,*N*-dimethyl-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepin-5-amine,

8'-chloro-1'-[(3*R*)-1-(pyridin-2-ylmethyl)pyrrolidin-3-yl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8-chloro-5-methoxy-1-[(3*R*)-1-(pyridin-3-ylmethyl)pyrrolidin-3-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8-chloro-5-methoxy-1-[(3*R*)-1-(pyridin-2-ylmethyl)pyrrolidin-3-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8'-chloro-1'-[(3*S*)-1-(pyridin-3-ylmethyl)pyrrolidin-3-yl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8'-chloro-1'-[(3*R*)-1-(pyridin-3-ylmethyl)pyrrolidin-3-yl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine],

8-chloro-5-methoxy-1-[(3*S*)-1-(pyridin-3-ylmethyl)pyrrolidin-3-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine,

8'-chloro-1'-[(3*S*)-1-(pyridin-2-ylmethyl)pyrrolidin-3-yl]-4'*H*,6'*H*-spiro[1,3-dioxolane-2,5'-[1,2,4]triazolo[4,3-*a*][1]benzazepine] and

8-chloro-5-methoxy-1-[(3*S*)-1-(pyridin-2-ylmethyl)pyrrolidin-3-yl]-5,6-dihydro-4*H*-[1,2,4]triazolo[4,3-*a*][1]benzazepine.

~~33~~14. A pharmaceutical composition comprising therapeutically effective amount of a compound of general formula (I) and/or salt thereof and/or geometric isomer thereof and/or stereoisomer thereof and/or enantiomer thereof and/or racemate thereof and/or diastereomer thereof and/or ~~biologically active metabolite thereof and/or prodrug thereof and/or~~ solvate thereof and/or hydrate thereof and/or polymorph thereof according to any of claims 1 to ~~32~~ 13 as active substance and a pharmaceutically acceptable excipient.

~~34~~15. A combinational composition comprising therapeutically effective amount of a compound of general formula (I) and/or salt thereof and/or geometric isomer thereof and/or stereoisomer thereof and/or enantiomer thereof and/or racemate thereof and/or diastereomer thereof and/or ~~biologically active metabolite thereof and/or prodrug thereof and/or~~ solvate thereof and/or hydrate thereof and/or polymorph thereof according to any of claims 1 to ~~32~~ 13 and one or more other active substances~~.~~

~~35. The combinational composition according to claim 34, wherein the one or more other active substances are~~ selected from the group consisting of psycholeptics, psychoanaleptics, antihypertensives, spasmolytics, antiepileptics or other agents.

~~36~~16. Use of ~~T~~the composition of any of claims ~~33~~ 14 to ~~35~~ 15 in the manufacture of a medicament for ~~use in~~ the treatment and/or prophylaxis of a disease or condition associated with the central and/or peripheral antagonisation of V1a receptor selected from the group consisting of various pathological conditions of the female sex organs, long-standing conditions in blood pressure control, conditions resulting from inappropriate secretion of vasopressin, anxiety, depression, aggression, disorders of the central nervous system where one of the symptoms and/or syndromes of the disease may be related to anxiety, depression, aggression or show comorbidity with them (autistic spectrum disorder, obsessive compulsive disorder, various forms of Down syndrome, post-traumatic stress disorder), aggressive behavioural disorders and/or irritability, behavioural hyperactivity disorders, cognitive disorders and other neuropsychiatric disorders.

~~37~~17. A process for the preparation of a pharmaceutical composition having V1a receptor antagonist activity comprising a therapeutically effective amount of a compound of general formula (I) and/or salt thereof and/or geometric isomer thereof and/or stereoisomer thereof and/or enantiomer thereof and/or racemate thereof and/or diastereomer thereof and/or ~~biologically active metabolite thereof and/or prodrug thereof and/or~~ solvate thereof and/or hydrate thereof and/or polymorph thereof according to any of claims 1 to ~~32~~ 13 as active substance with pharmaceutically acceptable excipients.

~~38~~18. Use of ~~T~~the compound of general formula (I) and/or salt thereof and/or geometric isomer thereof and/or stereoisomer thereof and/or enantiomer thereof and/or racemate thereof and/or diastereomer thereof and/or ~~biologically active metabolite thereof and/or prodrug thereof and/or~~ solvate thereof and/or hydrate thereof and/or polymorph thereof according to any of claims 1 to ~~32~~ 13 in the manufacture of a medicament for ~~use in~~ the treatment and/or prophylaxis of a disease or condition associated with the central and/or peripheral antagonisation of V1a receptor~~.~~

~~39. The compound for use according to claim 38, wherein the disease or condition associated with the central and/or peripheral antagonisation of V1a receptor is~~ selected from the group consisting of various pathological conditions of the female sex organs, long-standing conditions in blood pressure control, conditions resulting from inappropriate secretion of vasopressin, anxiety, depression, aggression, disorders of the central nervous system where one of the symptoms and/or syndromes of the disease may be related to

anxiety, depression, aggression or show comorbidity with them (autistic spectrum disorder, obsessive compulsive disorder, various forms of Down syndrome, post-traumatic stress disorder), aggressive behavioural disorders and/or irritability, behavioural hyperactivity disorders, cognitive disorders ~~or~~ and other neuropsychiatric disorders.

~~40. Use of a compound of general formula (I) and/or salt thereof and/or geometric isomer thereof and/or stereoisomer thereof and/or enantiomer thereof and/or racemate thereof and/or diastereomer thereof and/or biologically active metabolite thereof and/or prodrug thereof and/or solvate thereof and/or hydrate thereof and/or polymorph thereof according to any of claims 1 to 32 for the treatment and/or prophylaxis of a disease or condition associated with the central and/or peripheral antagonisation of V1a receptor.~~

~~41. The use according to claim 40, wherein the disease or condition associated with the central and/or peripheral antagonisation of V1a receptor is selected from the group consisting of various pathological conditions of the female sex organs, long-standing conditions in blood pressure control, conditions resulting from inappropriate secretion of vasopressin, anxiety, depression, aggression, disorders of the central nervous system where one of the symptoms and/or syndromes of the disease may be related to anxiety, depression, aggression or show comorbidity with them (autistic spectrum disorder, obsessive compulsive disorder, various forms of Down syndrome, post-traumatic stress disorder), aggressive behavioural disorders and/or irritability, behavioural hyperactivity disorders, cognitive disorders or other neuropsychiatric disorders.~~

~~42. Method for treating and/or preventing a disease or condition associated with V1a receptor function comprising administering, to the mammal to be treated, of a therapeutically effective amount of a compound of general formula (I) and/or salt thereof and/or geometric isomer thereof and/or stereoisomer thereof and/or enantiomer thereof and/or racemate thereof and/or diastereomer thereof and/or biologically active metabolite thereof and/or prodrug thereof and/or solvate thereof and/or hydrate thereof and/or polymorph thereof according to any of claims 1 to 32 alone or with pharmaceutically acceptable excipients.~~

~~43. The method according to claim 42, wherein the disease or condition associated with the central and/or peripheral antagonisation of V1a receptor is selected from the group consisting of various pathological conditions of the female sex organs, long-standing conditions in blood pressure control, conditions resulting from inappropriate secretion of vasopressin, anxiety, depression, aggression, disorders of the central nervous system~~

where one of the symptoms and/or syndromes of the disease may be related to anxiety, depression, aggression or show comorbidity with them (autistic spectrum disorder, obsessive compulsive disorder, various forms of Down syndrome, post traumatic stress disorder), aggressive behavioural disorders and/or irritability, behavioural hyperactivity disorders, cognitive disorders or other neuropsychiatric disorders.

4419. Use of The compound of general formula (I) and/or salt thereof and/or geometric isomer thereof and/or stereoisomer thereof and/or enantiomer thereof and/or racemate thereof and/or diastereomer thereof and/or biologically active metabolite thereof and/or prodrug thereof and/or solvate thereof and/or hydrate thereof and/or polymorph thereof according to any of claims 1 to 32 13 and one or more other active substances selected from the group consisting of psycholeptics, psychoanaleptics, antihypertensives, spasmolytics, antiepileptics or other agents in the manufacture of a medicament for use in the treatment and/or prophylaxis of a disease or condition associated with the central and/or peripheral antagonisation of V1a receptor selected from the group consisting of various pathological conditions of the female sex organs, long-standing conditions in blood pressure control, conditions resulting from inappropriate secretion of vasopressin, anxiety, depression, aggression, disorders of the central nervous system where one of the symptoms and/or syndromes of the disease may be related to anxiety, depression, aggression or show comorbidity with them (autistic spectrum disorder, obsessive compulsive disorder, various forms of Down syndrome, post-traumatic stress disorder), aggressive behavioural disorders and/or irritability, behavioural hyperactivity disorders, cognitive disorders and other neuropsychiatric disorders.

45. The combination for use according to claim 44, wherein the one or more other active substances are selected from the group consisting of psycholeptics, psychoanaleptics, antihypertensives, spasmolytics, antiepileptics or other agents.

4620. The compound selected from the group consisting of:

of formula (XIII) wherein R^1 is chlorine or bromine



.

tert-butyl (7-chloro-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-4-yl)carbamate, tert-butyl-(7-bromo-2-oxo-2,3,4,5-tetrahydro-1H-1-benzazepin-4-yl)carbamate,

47. The compound of formula (III) wherein R^1 is chlorine or bromine

.

tert-butyl-(7-chloro-2-thioxo-2,3,4,5-tetrahydro-1H-1-benzazepin-4-yl)carbamate,

tert-butyl-(7-bromo-2-thioxo-2,3,4,5-tetrahydro-1H-1-benzazepin-4-yl)carbamate,

48. The compound of formula (IV-a), the *tert*-butyl-(7-chloro-2-(methylsulfanyl)-4,5-dihydro-3*H*-1-benzazepin-4-yl)carbamate



49. The compound of formula (XXIX) wherein R^1 is chlorine or bromine



7-chloro-1,5-dihydrospiro[1-benzazepine-4,2'-[1,3]dioxolane]-2(3*H*)-one,

7-bromo-1,5-dihydrospiro[1-benzazepine-4,2'-[1,3]dioxolane]-2(3H)-one,

50. The compound of formula (XXV), the 4-{[*tert*-butyl(dimethyl)silyl]oxy}-7-chloro-1,3,4,5-tetrahydro-2*H*-1-benzazepin-2-one



51. The compound of formula (III-b), the 4-{[*tert*-butyl(dimethyl)silyl]oxy}-7-chloro-1,3,4,5-tetrahydro-2*H*-1-benzazepin-2-thione



52. The compound of formula (XLIV), the 7-chloro-4-methoxy-1,3,4,5-tetrahydro-2*H*-1-benzazepin-2-one



~~53. The compound of formula (III-c), the~~ 7-chloro-4-methoxy-1,3,4,5-tetrahydro-2*H*-1-benzazepine-2-thione

